The 2.5mg weight loss injection: what it does and why treatment starts here

Why do weight loss injections start at 2.5mg rather than a higher dose?

The short answer: to protect you from the side effects that come with jumping straight to a therapeutic dose. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it acts on two pathways involved in appetite regulation and gastric emptying. Slowing how quickly food leaves the stomach is part of what makes it effective, but it also explains why nausea, indigestion and changes in bowel habit are the most common early complaints.

Starting at 2.5mg gives the gut time to adapt. The approach is standard across the licensed dosing schedule: you stay at each level for roughly four weeks before your prescriber considers moving you to 5mg, then 7.5mg, and so on up to a maximum of 15mg. That step-by-step structure isn't bureaucracy; it's the mechanism the clinical evidence is built around. The large-scale trial data behind tirzepatide's UK licence (covering thousands of adults across the SURMOUNT programme) used exactly this titration model. For more on how the full schedule fits together, the weight loss injections dosage guide covers each stage in detail.

One practical point worth knowing: 2.5mg tirzepatide comes in the same KwikPen format as every other strength. Each pen delivers four weekly doses at the same concentration, the dose is set by the pen you're dispensed, not by dialling a number.

What side effects are typical at the starting dose, and when do they ease?

A question our prescribers hear most weeks: I felt fine on 2.5mg, does that mean it's working? Yes, broadly. Tolerating the starting dose well is actually the intended outcome at this stage. Common side effects at 2.5mg follow the same GI-led pattern as the rest of the schedule: nausea, constipation, burping, indigestion, and occasionally loose stools or fatigue. They tend to be most noticeable in the first few days after the first injection and again after each dose step, then settle.

The weight loss injections overview explains the general side-effect profile across licensed options. For tirzepatide specifically, the NHS patient information page covers what to watch for and when to seek help. If you experience severe, persistent stomach pain that radiates toward the back (with or without vomiting) that warrants prompt medical attention, as this can be a sign of pancreatitis, a known but uncommon risk the MHRA has flagged for GLP-1 medicines. Report any suspected side effects through the MHRA's Yellow Card scheme.

Keeping well hydrated and eating smaller, lower-fat meals during the starting weeks is consistently useful. Your prescriber and the Patient Information Leaflet are the right sources for personalised guidance on managing early effects.

Who reaches this starting dose through a legitimate UK route?

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 or above where at least one weight-related health condition is present, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The NICE appraisal of tirzepatide (TA1026) sets additional criteria for NHS access, which is rolling out in phases. Private treatment through a regulated pharmacy works differently: eligibility is still assessed by a prescriber, but there is no waiting list and no referral requirement.

If you're weighing up what private treatment costs, the guide to weight loss injection costs gives an honest breakdown of what a legitimate private price should include. At nume, a named GPhC-registered Independent Prescriber reviews every consultation (not software) and the treatment price covers the prescription, the medication, and aftercare.

It's also worth noting what the 2.5mg dose is not: it isn't a separate product, and it isn't a lower-grade option. Saxenda (liraglutide) follows a different titration structure entirely, you can read about that on the Saxenda dosage page if that's the product you're researching. Some searches for injection dosages also surface vitamin B12 and L-carnitine injections, which are not GLP-1 medicines and work through entirely different mechanisms; those are covered separately on the B12 injections page and the L-carnitine dosage page.

When does the 2.5mg dose increase, and who decides?

Your prescriber decides, not a fixed calendar. The standard schedule moves to 5mg after four weeks at 2.5mg, but that step happens only once your prescriber is satisfied that you've tolerated the starting dose. If side effects are still significant at four weeks, they may recommend staying at 2.5mg a little longer. Moving faster is not an option: increasing earlier than the licensed schedule doesn't improve outcomes and increases the likelihood of side effects that lead people to stop treatment altogether.

At each repeat, a prescriber reviews your response before the next supply is approved. That review matters. Evidence of how you're tolerating the current dose, any changes in your health, and your weight trajectory all feed into the decision. It's this ongoing clinical oversight (built into the process at every stage) that separates a regulated private service from sources that supply these medicines without proper assessment.

If you'd like to speak to a prescriber about where the 2.5mg starting dose fits into a treatment plan for you, the free consultation is the place to start. Our clinical team's approach is explained on the clinical team page.